Evidence map›Paper›PMID 36173534›Full record

ArticleMolecular neurobiology2022

Transplantation of Nasal Olfactory Mucosa Mesenchymal Stem Cells Benefits Alzheimer's Disease.

Chun-Gu Hong, Meng-Lu Chen, Ran Duan, Xin Wang, Zhi-Lin Pang, Li-Te Ge, Ming Lu, Hui Xie, Zheng-Zhao Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Chun-Gu Hong *Department of Orthopedics, Movement System Injury and Repair Research Center, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Meng-Lu Chen *Department of Sports Medicine, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Ran Duan *Department of Sports Medicine, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Xin WangDepartment of Sports Medicine, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Zhi-Lin PangDepartment of Sports Medicine, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Li-Te GeDepartment of Neurosurgery, Second Affiliated Hospital of Hunan Normal University (921 Hospital of PLA), Changsha, 410081, Hunan, China.
Ming Lu *Department of Neurosurgery, Second Affiliated Hospital of Hunan Normal University (921 Hospital of PLA), Changsha, 410081, Hunan, China. lumingcs163@126.com.
Hui Xie *Department of Orthopedics, Movement System Injury and Repair Research Center, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China. huixie@csu.edu.cn.
Zheng-Zhao Liu *Department of Orthopedics, Movement System Injury and Repair Research Center, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China. liuzhengzhao@csu.edu.cn.ORCID http://orcid.org/0000-0003-0659-2775
Central South University · CNHunan Normal University · CN

Funding

Fundamental Research Funds for Central Universities of the Central South University 2019zzts1042Fundamental Research Funds for Central Universities of the Central South University 2020zzts859National Natural Science Foundation of China 81974127National Natural Science Foundation of China 82172502
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a common neurodegenerative disease that contributes to 60-70% of dementia in elderly people and is currently incurable. Current treatments only relieve the symptoms of AD and slow its progression. Achieving effective neural regeneration to ameliorate cognitive impairment is a major challenge in the treatment of AD. For the first time, we alleviated symptoms of AD in APPswe/PS1dE9 mice (hereafter referred to as AD mice) by transplantation of olfactory mucosa mesenchymal stem cells (OM-MSCs). Our study demonstrated that OM-MSC transplantation promotes amyloid-β (Aβ) clearance, downregulates the inflammatory response, and increases the M2/M1 ratio; OM-MSCs promote the conversion of BV2 (microglia) from M1 to M2 and also Aβ clearance in SH-SY5Y

Indexed as

Alzheimer DiseaseMesenchymal Stem CellsMesenchymal Stem Cell TransplantationNeuroblastomaNeurodegenerative DiseasesAmyloid beta-PeptidesAnimalsDisease Models, AnimalHumansMiceMice, TransgenicOlfactory MucosaAmyloid beta-PeptidesAlzheimer’s diseaseMesenchymal stem cellsOlfactory mucosa mesenchymal stem cellsTransplantation

Identifiers

PMID36173534
OpenAlexW4297964518

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.